Pediatric Lymphoma Clinical Trials
Category:Pediatric
Status:Active
Displaying all 6 Trial
This research study is evaluating a novel drug called CUDC-907 as a possible treatment for resistant (refractory) pediatric solid tumors (including neuroblastoma), lymphoma, or brain tumors.
Diagnosis: Pediatric Solid Tumors, Pediatric Lymphoma
Phase: 1
Protocol Number: 16-371
This clinical trial studies the effects of dexrazoxane hydrochloride on biomarkers associated with cardiomyopathy and heart failure after cancer treatment. Studying samples of blood in the laborato...
Diagnosis: Pediatric Lymphoma, Pediatric Leukemia
Phase:
Protocol Number: 16-725
This is a 2-part study of pembrolizumab (MK-3475) in pediatric participants who have either advanced melanoma or a programmed cell death ligand 1 (PD-L1)-positive advanced, relapsed or refractory s...
Diagnosis: Pediatric Solid Tumors, Pediatric Lymphoma
Phase:
Protocol Number: 16-235
An open-label, global, multi-center study to evaluate the safety and pharmacokinetics of venetoclax monotherapy, to determine the dose limiting toxicity (DLT) and the recommended Phase 2 dose (RPTD...
Diagnosis: Pediatric Leukemia, Pediatric Solid Tumors, Pediatric Lymphoma
Phase:
Protocol Number: 17-617
Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients
This study is designed to investigate whether the use of copanlisib is safe, feasible and beneficial to pediatric patients with solid solid tumors or lymphoma that are recurrent or refractory to st...
Diagnosis: Pediatric Solid Tumors, Pediatric Lymphoma
Phase:
Protocol Number: 18-141
Phase 1 Study of the Dual MDM2/MDMX Inhibitor ALRN-6924 in Pediatric Cancer
This research study is studying a novel drug called ALRN-6924 as a possible treatment for resistant (refractory) solid tumor, brain tumor, lymphoma or leukemia. The drugs involved in this study are...
Diagnosis: Pediatric Leukemia, Pediatric Brain Tumor, Pediatric Lymphoma, Pediatric Solid Tumors
Phase:
Protocol Number: 18-284
